Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting No phase listed Observational

A Prospective, Randomized, Placebo-Controlled Double Blind, 18 Month Study Evaluating the Efficacy and Tolerability of Lithium Orotate 10 mg Daily in Patients With Alzheimer's Disease and Mild Cognitive Impairment.

ClinicalTrials.gov ID: NCT07947953

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07947953. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Tolerability of Lithium Orotate in Alzheimer's Disease and Mild Cognitive Impairment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a prospective, multi-center, randomized, placebo-controlled, double-blind clinical trial lasting 18 months. Participants will be randomized to 1:1 to Lithium Orotate or matching placebo. Double-blinding will be maintained for investigators, participants, and outcome assessors. An independent data monitoring committee will oversee safety. The study will utilize Lithium Orotate 5 mg twice daily. The U.S. Manufacturer is Nitricost. It is a synthetic, stable Lithium Salt. The Nutricost 5 mg capsules only contain Lithium Orotate. There is no Lithium Carbonate in the 5 mg product. The Lithium Carbonate is undesirable because it is sequestered in Amyloid Plaques. The Lithium Orotate has been shown to be resist degradation and sequestration by the Amyloid Plaques. Recruitment is 6 months. Treatment phase is 18 months. Follow up is 1 month for post treatment for safety. Inclusion Criteria is adults aged 50-90 years; Diagnosis of probable Alzheimer's Disease (per NIA-AA criteria) or MCI (per Peterson criteria). Baseline MMSE score of 18-26 (for AD) or 24-30 (for MCI). Participants must be stable on approved AD medications (if applicable) for \>3 months. Participants must provide informed consent (or via legally authorized representative). Exclusion Criteria includes: Severe renal impairment of eGFR \<40, or CKD III-IV, History of Bipolar disorder or other lithium contraindications, Concomitant use of medications interacting with Lithium (e.g., diuretics, NSAIDs), Significant comorbidities (e.g., uncontrolled hypertension, recent stroke), Pregnancy or breastfeeding, The Risk Benefit Ratio is extremely low. 1/100. The relative risk of using Lithium Orotate is extremely small compared to the possible significant benefits. The FDA has cleared the use of Lithium Orotate in this clinical trial. The Sample Size is 200 participants (100 per arm), powered to detect a 2-point difference in MMSE change (SD=4, a+-=0.05, power=80%, 20% attrition). Stratification by AD/MCI status and age. The Active Arm is Lithium Orotate capsules 10 mg orally daily. The Placebo Arm is Identical placebo capsules daily. Dosing of Lithium Orotate will be titrated down to 5 mg QD, if needed for tolerability. Compliance will be assessed via pill counts and patient diaries. The Primary Endpoint is change in MMSE score from baseline, assessed every 3 months. Secondary Endpoint is PET Scan changes of Amyloid burden and/or Tau pathology at baseline and 18 months. PET Scans are optional only for participants that have an allergy to the PET Scan radionuclide, or have significant difficulty in transfers or transports to the imaging facility. Some participants will likely be home bound and unable to comply. Safety and Incidence of adverse events (AEs), serious AEs and discontinuations will be monitored via common terminology criteria for adverse events (CTCAE). Tolerability will be monitored via vital signs, renal functions (eGFR), thyroid function (TSH) and electrolyte panels every 3 months.

Study identification

NCT ID
NCT07947953
Recruitment status
Not yet recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Koser, Robert B., MD PA
Other
Enrollment
200 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
50 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 18, 2026 (Estimated)
Primary completion
May 18, 2028 (Estimated)
Completion
May 18, 2028 (Estimated)
Last update posted
Nov 19, 2026

2026 – 2028

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Robert B Koser Md Bradenton Florida 34209 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07947953, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.